Literature DB >> 11751400

CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells.

A Ribas1, L H Butterfield, S N Amarnani, V B Dissette, D Kim, W S Meng, G A Miranda, H J Wang, W H McBride, J A Glaspy, J S Economou.   

Abstract

Genetic immunization of mice with dendritic cells (DCs) engineered to express a melanoma antigen generates antigen-specific, MHC-restricted, CD4-dependent protective immune responses. We wanted to determine the role of CD4 cells and CD40 ligation of MART-1 gene-modified DC in an animal model of immunotherapy for murine melanoma. CD4 knock-out (CD4KO) or antibody-depleted mice were immunized with DC adenovirally transduced with the MART-1 gene (AdVMART1/DC) with or without CD40 cross-linking. Tumor protection was absent in CD4-depleted mice, but protection was reestablished when the CD40 receptor was engaged using three different constructs. Transduction of DCs with vectors expressing the Th1 cytokines interleukin (IL)-2, IL-7, or IL-12 could not reproduce the CD40-mediated maturation signal in this model. CD8 T-cell depletion in CD4KO mice immunized with CD40-ligated DCs abrogated the protective response. Pooled analysis of CD40 cross-linking of AdVMART1/DC administered to wild-type C57BL/6 mice revealed an overall enhancement of antitumor immunity. However, this effect was inconsistent between replicate studies. In conclusion, maturation of AdVMART1-transduced DCs through the CD40 ligation pathway can promote a protective CD8 T-cell-mediated immunity that is independent of CD4 T-cell help.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11751400

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

Review 1.  Molecular mechanism and function of CD40/CD40L engagement in the immune system.

Authors:  Raul Elgueta; Micah J Benson; Victor C de Vries; Anna Wasiuk; Yanxia Guo; Randolph J Noelle
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

2.  CD40 engagement on dendritic cells, but not on B or T cells, is required for long-term control of murine gammaherpesvirus 68.

Authors:  Francesca Giannoni; Ashley Shea; Chandra Inglis; Lian Ni Lee; Sally R Sarawar
Journal:  J Virol       Date:  2008-09-03       Impact factor: 5.103

3.  Characterization of HPV18 E6-specific T cell responses and establishment of HPV18 E6-expressing tumor model.

Authors:  Ying Ma; Andrew Yang; Shiwen Peng; Jin Qiu; Emily Farmer; Chien-Fu Hung; T-C Wu
Journal:  Vaccine       Date:  2017-06-07       Impact factor: 3.641

4.  IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors.

Authors:  Kotaro Sasaki; Angela D Pardee; Yanyan Qu; Xi Zhao; Ryo Ueda; Gary Kohanbash; Lisa M Bailey; Hideho Okada; Ravikumar Muthuswamy; Pawel Kalinski; Per H Basse; Louis D Falo; Walter J Storkus
Journal:  J Immunother       Date:  2009-10       Impact factor: 4.456

5.  Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma.

Authors:  Eduardo Huarte; Jan Fisher; Mary Jo Turk; Diane Mellinger; Cathy Foster; Benita Wolf; Kenneth R Meehan; Camilo E Fadul; Marc S Ernstoff
Journal:  Cancer Lett       Date:  2009-06-06       Impact factor: 8.679

6.  Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.

Authors:  Lisa H Butterfield; Begonya Comin-Anduix; Lazar Vujanovic; Yohan Lee; Vivian B Dissette; Jin-Quan Yang; Hong T Vu; Elizabeth Seja; Denise K Oseguera; Douglas M Potter; John A Glaspy; James S Economou; Antoni Ribas
Journal:  J Immunother       Date:  2008-04       Impact factor: 4.456

7.  An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells.

Authors:  Lixin Zhang; Yucheng Tang; Hakan Akbulut; Daniel Zelterman; Phyllis-Jean Linton; Albert B Deisseroth
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-25       Impact factor: 11.205

8.  Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity.

Authors:  Leeann T Blalock; Jennifer Landsberg; Michelle Messmer; Jian Shi; Angela D Pardee; Ronald Haskell; Lazar Vujanovic; John M Kirkwood; Lisa H Butterfield
Journal:  Oncoimmunology       Date:  2012-05-01       Impact factor: 8.110

9.  CD8+ T cell-mediated control of distant tumours following local photodynamic therapy is independent of CD4+ T cells and dependent on natural killer cells.

Authors:  E Kabingu; L Vaughan; B Owczarczak; K D Ramsey; S O Gollnick
Journal:  Br J Cancer       Date:  2007-05-15       Impact factor: 7.640

10.  The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer.

Authors:  William A Freed-Pastor; Laurens J Lambert; Zackery A Ely; Nimisha B Pattada; Arjun Bhutkar; George Eng; Kim L Mercer; Ana P Garcia; Lin Lin; William M Rideout; William L Hwang; Jason M Schenkel; Alex M Jaeger; Roderick T Bronson; Peter M K Westcott; Tyler D Hether; Prajan Divakar; Jason W Reeves; Vikram Deshpande; Toni Delorey; Devan Phillips; Omer H Yilmaz; Aviv Regev; Tyler Jacks
Journal:  Cancer Cell       Date:  2021-08-05       Impact factor: 38.585

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.